Therapeutics News and Research

RSS

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms.

29 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

UC San Francisco has been awarded a Bill & Melinda Gates Foundation grant of $2.7 million over three years for a collaborative project aimed at reducing premature births.

29 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

28 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer.

28 Jan 2014

New versions of old antibiotic offers strategy for overcoming drug resistance

Research led by St. Jude Children's Research Hospital scientists has produced new versions of an old antibiotic that are active against difficult-to-treat tuberculosis; offers new strategy for overcoming drug resistance

28 Jan 2014

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

27 Jan 2014

TSRI professor wins 2014 Wolf Prize in chemistry

Chi-Huey Wong, professor of chemistry at The Scripps Research Institute (TSRI), has won the 2014 Wolf Prize in Chemistry for his pioneering contributions to the synthesis of compounds vitally important to biology and medicine.

25 Jan 2014

Antibe Therapeutics increases non-brokered private placement to a total of 2.27 million units

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").

25 Jan 2014

Scientists develop powerful RapidCaP mouse models for metastatic prostate cancer

Prostate cancer is the most common form of cancer in men. Affecting about 1 in 6 men, it is the second deadliest cancer. Research has been stymied by imperfect animal models of the disease, which are costly, take considerable time to develop, and fail to mimic the most lethal aspects of the illness.

25 Jan 2014

American Humane and TGen uncover genetic basis of obsessive-compulsive disorder in dogs

Every year, one out of every 88 children in the United States is diagnosed with some form of autism, with these numbers steadily rising over the last decade. Alarmingly, it is believed that now one of every 54 young boys has some form of the disease.

24 Jan 2014

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

e-Therapeutics plc today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials.

24 Jan 2014

Salmonella infections can reduce incidence of asthma, say researchers

Researchers from Germany have identified the mechanism by which Salmonella infections can reduce the incidence of asthma in mice. The research, which appears ahead of print in the journal Infection and Immunity, opens up new avenues of research that could lead to treatments.

24 Jan 2014

Therapeutics News and Research

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Researchers discover potential treatment for viral infection that causes illnesses in children

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

New versions of old antibiotic offers strategy for overcoming drug resistance

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

TSRI professor wins 2014 Wolf Prize in chemistry

Antibe Therapeutics increases non-brokered private placement to a total of 2.27 million units

Scientists develop powerful RapidCaP mouse models for metastatic prostate cancer

American Humane and TGen uncover genetic basis of obsessive-compulsive disorder in dogs

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

Salmonella infections can reduce incidence of asthma, say researchers

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News